News
Press Releases
Jan 31, 2023
Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort
...
Read MoreMay 22, 2022
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
...
Read MoreMay 17, 2022
Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022
Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...
Read More